Literature DB >> 8506315

Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.

L Whitesell1, D Geselowitz, C Chavany, B Fahmy, S Walbridge, J R Alger, L M Neckers.   

Abstract

We report experiments in the rat demonstrating the feasibility of intraventricular administration of oligodeoxynucleotides (ODNs) as a regional treatment approach to disorders within the central nervous system (CNS). Although we find little intrinsic nuclease activity in cerebrospinal fluid (CSF), phosphodiester ODNs are rapidly degraded by brain-associated alpha-exonuclease activity. Phosphorothioate ODNs, however, appear resistant to degradation in the CNS and, after intraventricular administration, we find they are cleared in a manner consistent with CSF bulk flow. Continuous infusion of ODN at 1.5 nmol/hr by miniosmotic pump can maintain micromolar concentrations of intact phosphorothioate ODN in CSF for at least 1 week without obvious neurologic or systemic toxicity. After infusion, extensive brain penetration and marked cellular uptake, especially by astrocytic cells, is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506315      PMCID: PMC46573          DOI: 10.1073/pnas.90.10.4665

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

Review 1.  Antisense inhibition of oncogene expression.

Authors:  L Neckers; L Whitesell; A Rosolen; D A Geselowitz
Journal:  Crit Rev Oncog       Date:  1992

2.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo.

Authors:  M Simons; E R Edelman; J L DeKeyser; R Langer; R D Rosenberg
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

3.  Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-( 14 C)inulin after intrathecal infusion.

Authors:  N H Bass; P Lundborg
Journal:  Brain Res       Date:  1973-03-30       Impact factor: 3.252

4.  3,4-Dihydroxyphenylethylamine and 5-hydroxytryptamine metabolism in the rat: acidic metabolites in cisternal cerebrospinal fluid before and after giving probenecid.

Authors:  G Curzon; P H Hutson; B D Kantamaneni; B J Sahakian; G S Sarna
Journal:  J Neurochem       Date:  1985-08       Impact factor: 5.372

5.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

6.  Monoclonal antibodies specific for glial fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides.

Authors:  E Debus; K Weber; M Osborn
Journal:  Differentiation       Date:  1983       Impact factor: 3.880

7.  In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide.

Authors:  L Whitesell; A Rosolen; L M Neckers
Journal:  Antisense Res Dev       Date:  1991
  7 in total
  36 in total

Review 1.  Gene therapy for brain tumors.

Authors:  K Bansal; H H Engelhard
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Suppression of cortical NMDA receptor function prevents development of orientation selectivity in the primary visual cortex.

Authors:  A S Ramoa; A F Mower; D Liao; S I Jafri
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

3.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

Review 4.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

Review 5.  Growth factors in gliomas: antisense and dominant negative mutant strategies.

Authors:  J W Campbell; I F Pollack
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats.

Authors:  M E Fundytus; K Yashpal; J G Chabot; M G Osborne; C D Lefebvre; A Dray; J L Henry; T J Coderre
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

7.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

8.  Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling.

Authors:  L Torner; N Toschi; A Pohlinger; R Landgraf; I D Neumann
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

9.  Antisense imaging of gene expression in the brain in vivo.

Authors:  N Shi; R J Boado; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

10.  Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain Kv1.6 channel subtype.

Authors:  Renato Pirisino; Carla Ghelardini; Alessandra Pacini; Nicoletta Galeotti; Laura Raimondi
Journal:  Br J Pharmacol       Date:  2004-04-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.